• 1
    Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;98:979987.
  • 2
    Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998;83:11041115.
  • 3
    Elghetany MT, Molina CP, Patel J, Martinez J, Schwab H, Velagaleti GVN. Expression of CD4 on peripheral blood granulocytes in a case of myelodysplastic syndrome in association with translocation (5;12). Cancer Genet Cytogenet 2002;136:15.
  • 4
    Elghetany MT, Martinez J, Patel J, Sackey K, Alter BP. Granulocytic surface marker abnomalities are detected only in patients with myelodysplastic syndrome and patients with Shwachman–Diamond syndrome but not other bone marrow failure syndromes. Blood 2000;98(Suppl):357A.
  • 5
    Barclay AN, Brown MH, Law SKL, McKnight AJ, Tomlinson MG, van der Merwe PA. The leukocyte antigen FactsBook. 2nd edition. San Diego: Academic Press; 1997. p 192193.
  • 6
    Knapp W, Majdic O, Bettelheim P, Liszka K, Aberer W, Stingl G. Typing of leukemic cells with monoclonal antibodies. Ann NY Acad Sci 1983;420:251260.
  • 7
    Rozman M, Cervantes F, Urbano-Ispizua A, Feliu E, Vives-Corrons J-L, Rozman C. Sequential study of myeloid differentiation antigens of neutrophil granulocytes in different phases of chronic myeloid leukemia: natural history and prognostic significance. Leukemia 1993;7:8085.
  • 8
    Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990;144:638641.
  • 9
    Terstappen LWMM, Safford M, Liken MR. Flow cytometric analysis of human bone marrow III. Neutrophil maturation. Leukemia 1990;4:657663.
  • 10
    Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989;46:183219.